GLP-1 receptor agonists like semaglutide produce significant weight loss but generate conflicting evidence regarding skeletal muscle mass preservation. Some studies document excessive muscle loss potentially leading to sarcopenia, while others suggest protective effects through improved muscle quality and reduced myosteatosis (fat infiltration within muscle tissue). The controversy stems from inconsistent body composition measurement methods and limited rigorous assessment of muscle function and structure in human studies. This uncertainty carries substantial implications for the millions using these blockbuster weight-loss medications. Muscle mass preservation becomes critical as we age, with sarcopenia linked to falls, fractures, and mortality risk. The conflicting data highlights a fundamental gap in how these drugs are studied—weight loss alone doesn't capture the full metabolic picture. If GLP-1 drugs genuinely improve muscle quality while maintaining function, modest mass reduction might be acceptable. However, older adults face higher baseline sarcopenia risk, making this population particularly vulnerable to potential muscle-wasting effects. The clinical challenge lies in distinguishing beneficial fat loss from problematic muscle loss, requiring more sophisticated monitoring than standard scales provide.